Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Willis

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Biotechnology Letters|January 6, 2011
Improved detergent-based recovery of polyhydroxyalkanoates (PHAs)Yung-Hun Yang, Christopher Brigham, Laura Willis, et al.
Emergency Radiology|July 10, 2024
Complications of pediatric macrocystic lymphatic malformations of the head and neck: a survival analysis of treated and untreated patientsGary Peiser, Rajat Chand, Joao G Amaral, et al.
AJR. American Journal of Roentgenology|June 24, 2006
Digital and screen-film mammography: comparison of image acquisition and interpretation timesEric A Berns, R Edward Hendrick, Mariana Solari, et al.
Pediatric Blood & Cancer|August 21, 2024
Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndromeAlexandra Zabeida, Jack J Brzezinski, Jonathan D Wasserman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2010
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patientsBianca Weinstock-Guttman, Robert Zivadinov, Jun Qu, et al.
Journal of Neuroimmunology|May 31, 2011
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating eventDana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2013
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating eventBianca Weinstock-Guttman, Robert Zivadinov, Dana Horakova, et al.
Plos One|January 16, 2013
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET studyDana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Haematologica|April 16, 2026
Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative studyTalya Wittmann Dayagi, Laura Willis, Staci D Arnold, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biotechnology Letters|January 6, 2011
Improved detergent-based recovery of polyhydroxyalkanoates (PHAs)Yung-Hun Yang, Christopher Brigham, Laura Willis, et al.
Emergency Radiology|July 10, 2024
Complications of pediatric macrocystic lymphatic malformations of the head and neck: a survival analysis of treated and untreated patientsGary Peiser, Rajat Chand, Joao G Amaral, et al.
AJR. American Journal of Roentgenology|June 24, 2006
Digital and screen-film mammography: comparison of image acquisition and interpretation timesEric A Berns, R Edward Hendrick, Mariana Solari, et al.
Pediatric Blood & Cancer|August 21, 2024
Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndromeAlexandra Zabeida, Jack J Brzezinski, Jonathan D Wasserman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2010
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patientsBianca Weinstock-Guttman, Robert Zivadinov, Jun Qu, et al.
Journal of Neuroimmunology|May 31, 2011
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating eventDana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2013
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating eventBianca Weinstock-Guttman, Robert Zivadinov, Dana Horakova, et al.
Plos One|January 16, 2013
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET studyDana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Haematologica|April 16, 2026
Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative studyTalya Wittmann Dayagi, Laura Willis, Staci D Arnold, et al.
Pageof 1